Advertisement
Advertisement
ALLO
Allogene Therapeutics, Inc. Common Stock
2.41
USDSponsored
+0.08
+3.61%
Mar 26, 15:59 UTC -4
Closed
Pre-Market
2.42
+0.01
+0.37%
ALLO Earnings Reports
Positive Surprise Ratio
ALLO beat 27 of 30 last estimates.
90%
Next Report
Date of Next Report
May 11, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/-$0.19
Implied change from Q4 25 (Revenue/ EPS)
--
/+11.76%
Implied change from Q1 25 (Revenue/ EPS)
--
/-32.14%
Allogene Therapeutics, Inc. Common Stock earnings per share and revenue
On Mar 12, 2026, ALLO reported earnings of -0.17 USD per share (EPS) for Q4 25, beating the estimate of -0.22 USD, resulting in a 22.97% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.83% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 12 analysts forecast an EPS of -0.19 USD, with revenue projected to reach -- USD, implying an increase of 11.76% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
Acumen Pharmaceuticals, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.46
Actual
-$0.41
Surprise
+11.29%
Rani Therapeutics Holdings, Inc. Class A Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.07
Surprise
-2.94%
Spero Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.20
Actual
$0.53
Surprise
+359.80%
Alpha Cognition Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.30
Surprise
-8.93%
Cognition Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.02
Surprise
+76.47%
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
Quantum Biopharma Ltd. Class B Subordinate Voting Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-Actual
-$0.71
Surprise
-
CollPlant Biotechnologies Ltd Ordinary Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.67
Surprise
-245.72%
FAQ
What were Allogene Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Allogene Therapeutics, Inc. Common Stock reported EPS of -$0.17, beating estimates by 22.97%, and revenue of $0.00, 0% as expectations.
How did the market react to Allogene Therapeutics, Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -2.83%, changed from $2.47 before the earnings release to $2.40 the day after.
When is Allogene Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 11, 2026.
What are the forecasts for Allogene Therapeutics, Inc. Common Stock's next earnings report?
Based on 12
analysts, Allogene Therapeutics, Inc. Common Stock is expected to report EPS of -$0.19 and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement